Fluidigm Joins Global Consortium of Cancer Prevention Experts
CANCERPREV Cross-Disciplinary Program Expands Knowledge of Cancer Development to Deliver New Insights into Prevention Strategies Principal Focus on Advancing Understanding of Breast and Skin Cancer Risks SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced its participation in CANCERPREV, a... Read more
QIAGEN fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems
Hilden, Germany and Ann Arbor, Michigan, September 17, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology.... Read more
Targeted sequencing with Oxford Nanopore: Fast, flexible, PCR-free Cas9 Sequencing Kit now available in store
Wed 16th September 2020 New Cas9 Sequencing Kit provides reagents for one-stop targeted sequencing, enabling scientists to cost-effectively sequence previously inaccessible target regions. Cas9 targeted sequencing with nanopore enables fast, simple, flexible target enrichment of long regions of interest – read lengths of over 100 kb have been observed to date. The approach is amplification-free, opening up regions... Read more
Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
Next-generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment New indication allows this first FDA-approved biomarker-based test to be used as triage for positive cobas HPV tests run on cobas 6800/8800 Systems in primary screening or co-testing programs More... Read more
PerkinElmer Launches DA 7350™ Instrument and Cloud-Based Software for Quality Control in Food Production
Solution helps producers reduce waste, increase product consistency and productivity and lower costs WALTHAM, Mass. – Sept 15, 2020 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today introduced the DA 7350™ instrument and Process Plus™ cloud-based software to provide continuous quality control for food and food ingredient manufacturing processes.... Read more
Thermo Fisher Scientific Further Expands Laboratory Plastics Production to Support COVID-19 Testing, Therapies and Vaccines
Thermo Fisher Scientific Further Expands Laboratory Plastics Production to Support COVID-19 Testing, Therapies and Vaccines WALTHAM, Mass. , Sept. 15, 2020 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it is investing more than $140 million to further expand its laboratory plastics consumables production to support significant global demand for... Read more
GE Healthcare’s Clariscan™ (gadoterate meglumine) Becomes Only FDA-Approved MRI Contrast Agent Available in Polymer Bottle
US FDA approves +PLUSPAK™ (polymer bottle) Pharmacy Bulk Package for the gadolinium-based contrast agent, Clariscan™ (gadoterate meglumine) As the only polymer bottle for an MRI contrast agent, Clariscan in +PLUSPAK offers the potential for increased workplace safety, efficiency, convenience and environmental advantages Clariscan has been approved in more than 65 countries globally, with more than... Read more
Luminex Corporation Declares Third Quarter Cash Dividend
AUSTIN, Texas, Sept. 15, 2020 /PRNewswire/ — On September 10, 2020, Luminex Corporation (Nasdaq:LMNX) (the “Company”), announced that its board of directors declared a cash dividend for the third quarter of 2020 of $0.09 per share of common stock payable on October 15, 2020 to stockholders of record as of the close of business September 24, 2020. About Luminex... Read more
Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System
MELBOURNE, Australia–(BUSINESS WIRE)–Illumina (NASDAQ: ILMN) announced today that the Australian public health laboratories will aim to sequence the virus genomes of all positive COVID-19 tests in Australia and track COVID-19 using genomics across the country, rather than state by state, under a ground-breaking initiative spearheaded by Australia’s public health laboratory organisations and leading industry partners.... Read more